Literature DB >> 1727474

In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Q Gao1, Z X Gu, M A Parniak, X G Li, M A Wainberg.   

Abstract

Drug-resistant variants of human immunodeficiency virus type 1 (HIV-1) have been isolated by in vitro selection. MT-4 cells were infected with either a laboratory strain (HIV-IIIB) or a clinical isolate (no. 187) of HIV-1 and maintained in medium containing subeffective concentrations of the drugs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI). By gradually increasing the drug concentration in the culture medium during propagation of the virus on fresh MT-4 cells, we were able to isolate variants of HIV-IIIB and clinical isolate 187 which showed up to 100-fold increases in resistance to the drugs. The drug resistance phenotypes remained stable after propagation of the variants in the absence of drug pressure for over 2 months. However, variants resistant to one drug showed little or no cross-resistance to the other, suggesting that the genetic bases for resistance to the compounds differed. Genotypic analysis of these nucleoside-resistant variants by polymerase chain reaction (PCR) with primer pairs previously shown to correspond to mutations responsible for resistance to AZT was also carried out. A heterogeneity of genotypes was observed, with known mutations at pol codons 70 and 215 occurring in most of the AZT-resistant variants generated from either HIV-IIIB or clinical strain 187. However, mutations in codons 67 and 219 were less frequently detected, and none of these changes were observed in each of four variants resistant to ddI. Cloning and sequencing studies of the reverse transcriptase coding region of two of the isolates were also performed and confirmed the PCR data that had been obtained. In addition to previously described mutation sites responsible for resistance to AZT, an HIV-IIIB-resistant variant was shown to be mutated at positions 108 (Val----Ala) and 135 (Ile----Thr), while a resistant variant of strain 187 was mutated at positions 50 (Ile----Val) and 135 (Ile----Val).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727474      PMCID: PMC238254     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.

Authors:  P Collins; B A Larder; N M Oliver; S Kemp; I W Smith; G Darby
Journal:  J Gen Virol       Date:  1989-02       Impact factor: 3.891

2.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

3.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

4.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

5.  Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.

Authors:  A J Japour; P A Chatis; H A Eigenrauch; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

7.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

8.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

10.  Related functional domains in virus DNA polymerases.

Authors:  B A Larder; S D Kemp; G Darby
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more
  64 in total

1.  Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses.

Authors:  S K Powell; M E Gates; G Langford; M L Gu; C Lockey; Z Long; E Otto
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Comparative analysis of HIV-1 resistance to AZT and AZT H-phosphonate in a cell culture.

Authors:  A G Pokrovskii; O A Plyasunova; Ya Yu Kiseleva; N M Gashnikova; N V Fedyuk
Journal:  Dokl Biochem Biophys       Date:  2002 May-Jun       Impact factor: 0.788

3.  Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

Authors:  J M Gobert; K M Remington; Y Q Zhu; T W North
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

Authors:  Hao Wu; Xiao-Min Zhang; Hao-Jie Zhang; Qiwei Zhang; Zhiwei Chen; Jian-Dong Huang; Shui-Shan Lee; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-08       Impact factor: 2.205

9.  Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors:  K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

10.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.